Kintegral Advisory LLC Takes Position in Avantor, Inc. (NYSE:AVTR)

Kintegral Advisory LLC purchased a new position in Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 24,257 shares of the company’s stock, valued at approximately $514,000.

Several other large investors have also recently modified their holdings of the stock. Versant Capital Management Inc grew its stake in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares during the period. Blue Trust Inc. boosted its stake in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after purchasing an additional 1,391 shares during the period. Gladius Capital Management LP purchased a new stake in shares of Avantor during the 4th quarter worth approximately $42,000. Montag A & Associates Inc. purchased a new stake in shares of Avantor during the 4th quarter worth approximately $43,000. Finally, TFO Wealth Partners LLC raised its holdings in shares of Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after acquiring an additional 2,031 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Stock Down 0.2 %

Shares of AVTR traded down $0.05 during mid-day trading on Wednesday, reaching $25.56. The company’s stock had a trading volume of 4,373,355 shares, compared to its average volume of 6,776,169. The business has a fifty day moving average of $23.26 and a 200 day moving average of $24.09. The company has a market cap of $17.36 billion, a price-to-earnings ratio of 65.54, a price-to-earnings-growth ratio of 2.71 and a beta of 1.32. Avantor, Inc. has a 1 year low of $16.63 and a 1 year high of $28.00. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89.

Avantor (NYSE:AVTR) last released its earnings results on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. The business had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%. As a group, analysts forecast that Avantor, Inc. will post 1.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on AVTR. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of Avantor in a research note on Monday, July 29th. Robert W. Baird raised their price objective on Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Morgan Stanley raised their price target on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Evercore ISI lowered their price target on Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, TD Cowen raised their price objective on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Avantor currently has an average rating of “Moderate Buy” and an average target price of $27.40.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.